<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fenofibrate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01039</strong>&#160; (APRD00405)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01039/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01039/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01039.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01039.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01039.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01039.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01039.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01039">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fenofibrato</td><td>Spanish</td><td>INN</td></tr><tr><td>Fenofibratum</td><td>Latin</td><td>INN</td></tr><tr><td>Fenofibric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Finofibrate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>FNF</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Antara</td><td>Oscient Pharmaceuticals</td></tr><tr><td>Fenogal</td><td>SMB Laboratories</td></tr><tr><td>Fenoglide</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>FIBRICOR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lipanthyl</td><td>Abbott</td></tr><tr><td>Lipidil</td><td>lbirn</td></tr><tr><td>Lipofen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lofibra</td><td>Teva</td></tr><tr><td>TriCor</td><td>Abbott</td></tr><tr><td>Triglide</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trilipix</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypolipidemic-agents">Hypolipidemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>49562-28-9</td></tr><tr><th>Weight</th><td>Average: 360.831<br>Monoisotopic: 360.112836867</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>21</sub>ClO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>YMTINGFKWWXKFG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzophenones</td></tr><tr><th>Direct parent</th><td>Benzophenones</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenoxyacetic Acid Derivatives; Acetophenones; Benzoyl Derivatives; Phenol Ethers; Alkyl Aryl Ethers; Chlorobenzenes; Aryl Chlorides; Carboxylic Acid Esters; Ketones; Polyamines; Enolates; Organochlorides</td></tr><tr><th>Substituents</th><td>phenoxyacetate; acetophenone; benzoyl; phenol ether; chlorobenzene; alkyl aryl ether; aryl chloride; aryl halide; ketone; carboxylic acid ester; enolate; ether; polyamine; carboxylic acid derivative; carbonyl group; organochloride; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)</td></tr><tr><th>Pharmacodynamics</th><td>Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.</td></tr><tr><th>Mechanism of action</th><td>Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.</td></tr><tr><th>Absorption</th><td>Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)]</li>
	<li>30 L [healthy adults]</li>
</ul></td></tr><tr><th>Protein binding</th><td>~99% (Serum protein binding)</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.</td></tr><tr><th>Half life</th><td>20 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>1.2 L/h [Eldery]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.987</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9334</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.648</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5571</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5995</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7632</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9042</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7897</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9147</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6735</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7599</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.7619</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7088</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6373
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9918
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2250 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9887
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9083
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories</li>
<li>Lupin atlantis holdings sa</li>
<li>Impax laboratories inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>Cipher pharmaceuticals inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Shionogi pharma inc</li>
<li>Skyepharma ag</li>
<li>Ar holding co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.ethypharm-pharmaceutical.com">Ethypharm</a></li>
<li>Fournier Pharma Inc.</li>
<li>Galephar Pharmaceutical Research Inc.</li>
<li>Gate Pharmaceuticals</li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li><a href="http://www.karalexpharma.com">Karalex Pharmaceuticals</a></li>
<li><a href="http://www.kowapharma.com">Kowa Pharmaceuticals America Inc.</a></li>
<li>Laboratories Fournier Sca</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li>Oscient Pharmaceuticals</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Promex Medical Inc.</li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li>Reliant Pharmaceuticals</li>
<li>Resource Optimization and Innovation LLC</li>
<li>Sciele Pharma Inc.</li>
<li><a href="http://www.shionogi-inc.com">Shionogi Pharma Inc.</a></li>
<li><a href="http://www.skyepharma.fr">Skyepharma Production Sas</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Fenofibrate may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Fenofibrate may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Fenofibrate may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00046">Insulin Lispro</a></td><td>Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy. </td></tr><tr><td><a href="/drugs/DB00175">Pravastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01098">Rosuvastatin</a></td><td>May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01586">Ursodeoxycholic acid</a></td><td>The fibric acid derivative decreases the effect of ursodiol</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Increased absorption- take with meals.</li></ul></td></tr></tbody></table>